A Multicentre, Phase 1B/2 Study of Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naive Advanced or Metastatic Biliary Tract Cancer
Latest Information Update: 18 Apr 2023
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Varlitinib (Primary)
- Indications Adenocarcinoma; Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors ASLAN Pharmaceuticals
- 22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium
- 12 Jan 2021 Status changed from active, no longer recruiting to discontinued.
- 18 Nov 2020 Status changed from recruiting to active, no longer recruiting.